Repligen

908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook

Retrieved on: 
Monday, March 7, 2022
Medical Devices, Health, Research, Pharmaceutical, Science, Biotechnology, Private Securities Litigation Reform Act, Adoption, Research, Machine learning, Security (finance), United States Army, U.S. Securities and Exchange Commission, Army of the United States, Mass spectrometry, Growth, Repligen, Webcast, Board, Goal, SEC, Company, Advanced Micro Devices, Inc. v. Intel Corp., Marketing, CEO, MASS, Nasdaq, Therapy, Video game, Pharmaceutical industry, Aquaculture

Gross profit was $9.1 million for the fourth quarter of 2021, compared to $2.6 million for the corresponding prior year period.

Key Points: 
  • Gross profit was $9.1 million for the fourth quarter of 2021, compared to $2.6 million for the corresponding prior year period.
  • Operating expenses were $12.7 million for the fourth quarter of 2021, compared to $6.5 million for the corresponding prior year period.
  • 908 Devices expects full year 2022 revenue to be in the range of $52 million to $55 million, representing 23% to 30% growth over full year 2021.
  • 908 Devices will host a conference call to discuss the fourth quarter and full year 2021 financial results after market closes on Monday, March 7, 2022 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

Retrieved on: 
Wednesday, March 2, 2022
General Health, Science, Health, Research, Private Securities Litigation Reform Act, Thermo Fisher Scientific, Research, Machine learning, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, Knowledge, Board of directors, Mass spectrometry, Applied Biosystems, Repligen, Board, SEC, Company, Repligen Corporation Award in Chemistry of Biological Processes, TrafFix Devices, Inc. v. Marketing Displays, Inc., CEO, MASS, Nasdaq, Life Technologies, Therapy, Management

Hunt, President and CEO, Repligen Corporation (Nasdaq: RGEN), to serve on its Board of Directors effective immediately.

Key Points: 
  • Hunt, President and CEO, Repligen Corporation (Nasdaq: RGEN), to serve on its Board of Directors effective immediately.
  • I am delighted to welcome Tony to the 908 Devices Board of Directors, said Kevin Hrusovsky, Chairman of 908 Devices.
  • I am honored to join the 908 Devices Board at this exciting stage of the companys journey, said Mr. Hunt.
  • 908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications.

Repligen Launches AAV Affinity Resins for Gene Therapy Purification

Retrieved on: 
Tuesday, February 15, 2022
NASDAQ, AAV, CEO, Repligen Corporation Award in Chemistry of Biological Processes, Repligen, Gene, Phrase, U.S. Securities and Exchange Commission, Solution, Vaccine, Security (finance), Leadership, Annual report, LinkedIn, Twitter, Economics, AAV2, General manager, GLOBE, Fine chemical

The resins AVIPure - AAV9, AVIPure - AAV8, and AVIPure - AAV2 were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors used today.

Key Points: 
  • The resins AVIPure - AAV9, AVIPure - AAV8, and AVIPure - AAV2 were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors used today.
  • AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases1.
  • Vikas Gupta, Vice President and General Manager, Downstream Bioprocessing and Gene Therapy at Repligen said, These AVIPure resins are powerful tools in our growing arsenal of unique and differentiated solutions for gene therapy manufacturing.
  • Kevin Isett, President and CEO of Avitide said, We are so pleased to introduce our AVIPure resins, which directly address the need for more advanced affinity solutions for gene therapy workflows.

Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference

Retrieved on: 
Friday, February 11, 2022
NASDAQ, Time, Repligen Corporation Award in Chemistry of Biological Processes, Repligen, Leadership, LinkedIn, Twitter, Conference, GLOBE, EST, Pharmaceutical industry

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11thAnnual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022.

Key Points: 
  • WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11thAnnual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022.
  • Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, Feb. 18, at 3:00 p.m. EST.
  • Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs.
  • For more information about the company, including Repligen news releases, see our website at www.repligen.com .

Repligen to Report Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, February 3, 2022
EST, Webcast, Repligen Corporation Award in Chemistry of Biological Processes, NASDAQ, Twitter, Investor relations, U.S. Securities and Exchange Commission, Company, Repligen, GLOBE, Time, Security (finance), LinkedIn

WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022.

Key Points: 
  • WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022.
  • The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2021.
  • The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers.
  • Both the conference call and webcast will be archived for a period of time following the live event.

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 30, 2021
Twitter, Repligen Corporation Award in Chemistry of Biological Processes, GLOBE, Leadership, NASDAQ, Repligen, EST, LinkedIn, Time

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40thAnnual J.P. Morgan Healthcare conference being held January 10-13.

Key Points: 
  • WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40thAnnual J.P. Morgan Healthcare conference being held January 10-13.
  • Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.
  • Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs.
  • For more information about the company, including Repligen news releases, see our website at www.repligen.com .

Synthace Raises $35M to Expand Access to Its Revolutionary R&D Technology for Life Changing Research

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Science, Other Science, Research, BioTek, Intelligence, Industry, Agtech, R, Cornerstone, Repligen, CEO, Farmer, Impossible Foods, COVID, McKinsey & Company, Growth, Automation, Investment, D, Facebook, Data analysis, Lead, Sofinnova, Future, Vaccine, Molecular biology, Meta, Solution, Therapy, Zoom, Drug discovery, Communication, GTM, Biology, Marketing, Horizons Ventures, Drug development, Management, Fine chemical, Biotechnology, Health, Science, Other Science, Research, Horizons Ventures, Sofinnova Partners, Synthace, HORIZONS VENTURES, SOFINNOVA PARTNERS, SYNTHACE

The investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to radically reinvent the full value chain of life sciences R&D.

Key Points: 
  • The investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to radically reinvent the full value chain of life sciences R&D.
  • But to maximize impact, we need to expand access and reach to customers across the globeat scale.
  • This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries.
  • To learn more about how Synthace is transforming life sciences for a better future visit www.synthace.com .

Repligen Corporation to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, November 12, 2021
Leadership, Investor relations, Repligen, NASDAQ, EST, Repligen Corporation Award in Chemistry of Biological Processes, Twitter, Conference, GLOBE, LinkedIn, Time, Pharmaceutical industry

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.

Key Points: 
  • WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.
  • Hunt, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, November 17, at 8:00 a.m. EST.
  • Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs.
  • For more information about the company, including Repligen news releases, see our website at www.repligen.com .

Repligen Releases Inaugural Sustainability Report

Retrieved on: 
Friday, November 5, 2021
People, Value, Achievement, United Nations Global Compact, Sustainable Development Goals, Society, First Nations in Ontario, COP, Repligen, NASDAQ, CEO, UN, Repligen Corporation Award in Chemistry of Biological Processes, Global, GRI, Board, Twitter, Communication, Company, Environment, ESG, GLOBE, LinkedIn, United Nations

WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Companys website .

Key Points: 
  • WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Companys website .
  • As a participant of the United Nations Global Compact (UNGC) since July 2020, this report also serves to fulfill Repligens first Communication on Progress (COP) commitment.
  • Hunt, President and CEO of Repligen said, The release of our first sustainability report is an important achievement for the Company and sets a strong foundation for future progress.
  • For more information about the company, including Repligen news releases, see our website at www.repligen.com .

Repligen to Report Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, October 14, 2021
Repligen, Investor relations, Time, LinkedIn, Repligen Corporation Award in Chemistry of Biological Processes, Security (finance), Conference, GLOBE, U.S. Securities and Exchange Commission, Company, Conference call, EDT, Twitter, NASDAQ

WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2021.

Key Points: 
  • Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT
    WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28, 2021.
  • The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2021.
  • The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers.
  • For more information about the company, including Repligen news releases, see our website at www.repligen.com .